Friday, 18 February 2011

Molecular Biotechnology

Perhaps the most powerful use of biotechnology for the development of human welfare has been in the field of molecular biotechnology. The powerful revolution in medicine over the past ten years has been in the field of genomic research, which has completely transformed the conventional medicine in the field of molecular medicine. The unveiling remarkable almost complete human genome in June 2000 and the release of the genetic code, in February 2001, was instrumental in deciphering the search path breaking and miracle drugs and the demand for the scientific community. So he created jubilation among health care workers around the world, but at the same time, the requests raised several ethical, legal and social too (ELSI).

The progress of research in genomic medicine in India in the field of cancer genomics, vaccines, genomics, microbial, pharmacogenomics, vector genomics, neurogenetics and molecular basis of disease has led to the development of new drugs and research into new treatments for conditions that were considered fatal in the past.

While new developments are underway in the area, the need to further enhance the proven technologies such as diagnostics and vaccines and uses them to apply also in the process. And 'here that Indian industry will make further efforts to take advantage of a revolution in biotechnology. This shows that if the Indian industry is strong in product development and marketing of commercial benefits of biotechnology in India does not have the necessary infrastructure for R & D molecular modeling, protein engineering, medicine and the design of immunological studies . This problem must be treated immediately to save on research initiatives.

Another aspect to consider is that different technologies in the field of molecular biotechnology have the potential to improve productivity and increase the number and quality of new drugs, allowing more and more diverse genomic targets for drug quality and acceleration of clinical development by designing better tests have clearly shown that the improved safety, efficiency and compliance. According to one estimate, improvising medical outcomes using well-developed drugs and diagnostics, pharmaceutical companies could benefit from the order of U.S. $ 200-500 in additional revenue for each drug. Apex scientific bodies in India, for example, CSIR, ICMR, DBT has initiated national programs to identify and characterize novel drug targets, particularly in the field of tuberculosis, malaria, leishmaniasis, etc., as well as new therapeutic targets for disorders diabetes, cardiovascular disease and neurological disorders. In addition, there is also preparing a proposal to undertake single-nucleotide polymorphisms (SNPs) mapping in over 500 genes to identify and characterize the Indian population, genes associated with susceptibility to malaria, tuberculosis, diabetes and cardiovascular diseases and neurological diseases, which are more common in the Indian context.